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OBJECTIVE—To evaluate pregnancy outcomes according to 2009 Institute of Medicine (IOM)
gestational weight gain guidelines.
METHODS—This study is a secondary analysis of a preeclampsia prevention trial among
nulliparas carrying singletons. Odds ratios and 95% confidence intervals (adjusted for maternal
age, race, smoking, and treatment group) were calculated based on total weight gain below or
above the IOM guidelines, stratified by prepregnancy body mass index (BMI). The referent group
was weight gain within the guidelines.
RESULTS—Of 8,293 pregnancies, 9.5% had weight gain below, 17.5% within, and 73% above
IOM guidelines. With excess weight gain, all BMI categories had an increased risk of
hypertensive disorders; normal weight and overweight women also had increased risk of cesarean
delivery and infant birth weight at or above the 90th centile but a decreased risk of weight below
the10th centile. There were no consistent associations with insufficient weight gain and adverse
outcomes.
CONCLUSION—Excess weight gain was prevalent and associated with an increased risk of
hypertensive disorders, cesarean delivery and large for gestational age infants..
Introduction
In 2009, the Institute of Medicine (IOM) released new guidelines for weight gain during
pregnancy. (1) The recommendation is for underweight, normal weight, overweight, and
obese women to gain 28–40, 25–35, 15–25, and 11–20 pounds, respectively. Changes from
the initial guidelines set forth in 1990 include: a range for weight gain in obese women
instead of a lower limit and a change in classification parameters resulting in the
classification of fewer women as underweight and more women as overweight.
The current and previous recommendations are based on a variety of evidence, from expert
opinion to population-based cohort studies. The majority of the evidence is rated as fair to
poor. (2) The larger studies are primarily from self-reported questionnaires or population
cohorts from countries other than the United States. Therefore, using data from a large
multicenter trial conducted in the United States, we evaluated maternal and perinatal
outcomes vis-à-vis the new IOM guidelines.
Materials and Methods
This study is a secondary analysis of a multicenter, placebo-controlled randomized double-
blind trial evaluating the use of vitamins C and E to prevent serious complications
associated with pregnancy related hypertension. The trial was conducted from 2003–2008
by 16 centers in the Eunice Kennedy Shriver National Institute of Child and Human
Development Maternal-Fetal Medicine Units Network. (3) Women were eligible for this
trial if they were nulliparous (no previous pregnancy lasting more than 19 6/7 weeks) and
carrying a singleton gestation between 9 and 16 weeks according to a previously described
algorithm that includes the date of the last menstrual period (if reliable) and the earliest
ultrasound examination. (4) Exclusion criteria included elevated blood pressure (systolic of
135mm Hg or higher or diastolic of 85mm Hg or higher), proteinuria (300mg in a 24 hour
collection or higher or more than trace protein on a urine dipstick), pregestational diabetes,
treatment with antiplatelet or non-steroidal anti-inflammatory drugs, uterine bleeding within
the week prior to recruitment, uterine malformation, serious medical condition (e.g.
epilepsy), known fetal anomaly or aneuploidy, in vitro fertilization resulting in the current
pregnancy, and illicit drug or alcohol abuse. In the original trial, the treatment (1000mg of
vitamin C and 400 IU of vitamin E) and placebo (mineral oil) capsules were matching and
neither the patients nor the investigators were aware of the treatment assignments. The
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simple urn method, with stratification according to clinical center, was used by the data
coordinating center to create a randomization sequence.
Women were eligible for this secondary analysis if their height and self-reported
prepregnancy weight were recorded at study entry and a weight measured and recorded
during a prenatal visit within two weeks prior to delivery. They were excluded from this
secondary analysis if they delivered prior to 20 weeks, died prior to delivery, had an
abortion, or their infant was found to have a major congenital malformation.
All maternal and neonatal data were collected by certified research personnel at each center
and entered into a database managed by an independent data coordinating center. Height and
self-reported prepregnancy weight were used to calculate the prepregnancy body mass index
(BMI) in kg/ m2. Weight gain during pregnancy was calculated by subtracting the
prepregnancy weight from the last recorded pregnancy weight.
The outcomes for this secondary analysis were gestational hypertension, preeclampsia,
cesarean delivery, indicated preterm birth, spontaneous preterm birth, birth weight at or
above the 90th centile (large for gestational age-LGA) and birth weight less than the 10th
centile (small for gestational age-SGA). Gestational hypertension was defined on the basis
of systolic pressure of greater than or equal to 140mm Hg or a diastolic pressure of greater
than or equal to 90mm Hg on two separate occasions 2– 240 hours apart after 20 weeks of
gestation in the absence of proteinuria. Preeclampsia was defined as gestational
hypertension with either proteinuria, defined as greater than or equal to 300mg in a 24 hour
sample, or, if a 24-hour sample was not available, 2+ or higher on dipstick testing (3), or a
protein:creatinine ratio of greater than or equal to 0.35 (3), pulmonary edema,
thrombocytopenia, or eclampsia. Preterm birth was defined as delivery prior to 37 weeks’
gestation. Birth weight centiles were adjusted for maternal height, weight, ethnicity,
gestational age, and fetal gender. (5) Although we were interested in gestational diabetes as
an outcome, the fact that many if not most women with this diagnosis have their diets
modified in such a way as to limit maternal weight gain (and fetal growth), we did not
include it as a dependent variable.
The data were stratified into groups based on prepregnancy BMI: underweight (less than
18.5 kg/m2), normal weight (18.5–24.9 kg/m2), overweight (25–29.9 kg/m2), and obese
(greater than or equal to 30.0 kg/m2). Categorical variables were compared using the chi-
square test and continuous variables with the Kruskal-Wallis test. The Cochran-Armitage
test for linear trend was used to compare the three weight gain categories (below, within and
above). For each category of BMI, logistic regression was used to calculate odds ratios and
95% confidence intervals for outcomes based on total gestational weight gain above or
below the guidelines. Weight gain was calculated based on completed weeks’ gestation. The
expected weight gain was determined by using the IOM recommendations of 1.1–4.4
pounds in the first trimester (through 13 weeks) for all women regardless of prepregnancy
BMI and combining it with the week specific guidelines for prepregnancy BMI of 1–1.3,
0.8–1, 0.5–0.7, and 0.4–0.6 pounds per week for underweight, normal weight, overweight,
and obese women, respectively for the remainder of pregnancy up to the time of last weight
within 2 weeks of delivery. (1) For example, if the prepregnancy weight of an overweight
female was 160 lbs and her last weight prior to delivery was measured at 37 weeks, the
recommended weight gain for her would be 13.1–21.2 lbs (1.1–4.4 pounds for the first
trimester and a range of 0.5–0.7 lbs per week for the remaining 24 weeks). A second
analysis was also performed in a similar manner using the weight recorded at study entry
instead of the self-reported prepregnancy weight in the same group of women. The main
difference in this analysis was expected weight gain during pregnancy was calculated by
using the second trimester recommendations for weight gain per week based on the BMI at
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study entry (and not the expected weight gain for the first trimester). For example, if the first
recorded weight for an overweight female was 160 lbs at 11 weeks gestation and her last
weight prior to delivery was measured at 37 weeks, the recommended weight gain for her
would be 13–18.2 lbs (0.5–0.7 lbs per week from gestation at study entry to the last recorded
weight [26 weeks total]).
The referent group in each weight category was weight gain within the guidelines.
Adjustments were made for maternal age, smoking, and race, all of which were determined a
priori as potential confounders. Adjustments were also made for treatment group given the
analyzed cohort. A p-value of < 0.05 was considered statistically significant; no adjustments
were made for multiple comparisons. Analyses were performed using SAS Software (SAS
Institute, Cary, North Carolina). This study was exempt from Institutional Review Board
approval at Women & Infants Hospital.
Results
Of the 10,154 women who underwent randomization in the original trial, outcome data was
available on 9,969 women. Of these women, prepregnancy weight was not recorded for 203,
1 died prior to delivery, 114 delivered prior to 20 weeks, 9 had an intentional abortion after
20 weeks, and 99 had a major fetal malformation. This left 9,543 women, of whom 1,250
did not have a weight recorded within 2 weeks prior to delivery, resulting in a cohort for this
secondary analysis of 8,293 women. Of these women, 389 (4.7%) were underweight, 4,522
(54.5%) of normal weight, 1,937 (23.4%) overweight, and 1,445 (17.4%) were obese based
on their prepregnancy BMI. (Table 1) Of note, there was a high degree of concordance
between prepregnancy BMI and BMI at study entry, with ρ=0.96.
We first evaluated the relationship between prepregnancy BMI category and weight gain
according to the IOM guidelines and found that the majority (73%) of women gained more
weight than recommended, fewer than 1 in 5 (17.5%) stayed within the guidelines, while 1
in 10 (9.5%) gained less than recommended (Table 2). In the overall cohort, the outcome
rates were significantly different in women who gained more than recommended compared
with women who gained within or below the guidelines (32% vs 21% for gestational
hypertension and preeclampsia combined, 27% vs 19% for cesarean delivery, 11% vs 15%
for SGA and 12% vs 7% for LGA, Table 3).
We then stratified outcomes by prepregnancy BMI and used a multivariable model to
compare women who gained more than recommended and women who gained less than
recommended with women who gained within the guidelines. After adjusting for maternal
age, race, smoking, and treatment group, women with a normal pre-pregnancy BMI who
gained above the IOM guidelines (Table 4) were at increased risk of developing gestational
hypertension (OR 1.5, 95% CI 1.2–1.8) or preeclampsia (OR 2.5, 95% CI 1.6–3.9),
undergoing cesarean delivery (OR 1.6, 95% CI 1.3–2.0), and delivering an LGA infant (OR
1.7, 95% CI 1.3–2.3). They were less likely to deliver an SGA infant (OR 0.6, 95% CI 0.5–
0.7). Similarly, women who were overweight prior to pregnancy and gained more than
recommended were more likely to develop preeclampsia (OR 4.2, 95% CI 1.7–10.4),
undergo cesarean delivery (OR 1.8, 95% CI 1.2–2.6), and deliver an LGA neonate (OR 2.5,
95% CI 1.3–4.5). They were also 60% less likely to deliver an SGA infant (OR 0.4, 95% CI
0.3–0.6). Women who were obese prior to pregnancy and gained more than recommended
had an increased risk of preeclampsia (OR 1.9, 95% CI 1.0–3.3).
Women with a normal prepregnancy BMI who gained less than recommended (Table 5) had
a reduced risk of delivering an LGA infant (OR 0.5, 95% CI 0.3–0.8) but an increased risk
of spontaneous preterm birth (OR 2.0, 95% CI 1.3–3.2). Women with a prepregnancy BMI
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in the obese category were more likely to have an SGA infant if they did not gain the
recommended amount of weight (OR 1.7, 95% CI 1.1–2.8).
Weight was recorded at first study visit in 8,291 women. Based on these weights, 232
women (2.8%) were underweight, 4,155 (50%) were normal weight, 2199 (27%) were
overweight, and 1705 (21%) were obese at study entry. A total of 6,235 (75%) women
gained above the recommended guidelines, 1,224 (15%) stayed within the guidelines, while
only 832 (10%) did not gain the recommended weight.
Separate analyses performed using first recorded study weight yielded similar results to
analyses based on self-reported prepregnancy weight with the following exceptions:
underweight and normal weight women gaining above the guidelines were no longer at a
statistically significant risk to develop gestational hypertension (OR 0.5, 95% CI 0.2–1.6
and OR 1.2, 95% CI 0.9–1.4, respectively), and women in the overweight group were at
increased risk to develop gestational hypertension (OR 1.8, 95% CI 1.1–2.7). In women that
did not gain the recommended amount, there were only three differences in outcomes when
analyzed by first study visit weight: normal weight women were less likely to develop
gestational hypertension (OR 0.6, 95% CI 0.4–0.9) and more likely to have an SGA neonate
(OR 1.9, 95% CI 1.4–2.6), and there was no longer an association between obese mothers
with inadequate weight gain and SGA (OR 1.5, 95% CI 0.9–2.5).
Discussion
In our cohort of 8,293 nulliparas, we made two important observations about weight gain in
pregnancy. First, approximately three of every four women gained more weight than is
recommended by the new IOM guidelines. Second, this excessive weight gain was
associated with several adverse pregnancy outcomes. In general, excessive weight gain was
associated with hypertensive disorders of pregnancy, delivering an LGA infant and
undergoing a cesarean delivery. For some BMI categories, these increased risks were
statistically significant at the p < 0.05 level, while in others they were not. Even so, the
direction of association was the same across all categories. Conversely, except for obese
women, the risk of delivering an SGA infant was reduced by weight gain above the
guidelines.
There are few published studies examining outcomes in relation to the new IOM guidelines.
De le Torre et al, in a retrospective cohort study, assessed the association between adherence
to the new guidelines and pregnancy related hypertension (6). Their findings are consistent
with ours. They found an increased risk of pregnancy related hypertension (preeclampsia
and gestational hypertension) in all women except those that were underweight prior to
pregnancy with excessive weight gain, while we found this association regardless of
prepregnancy BMI. They also make the important point that while overweight and obese
women are at risk for hypertensive disorders regardless of weight gain, excessive weight
gain further increases that risk.
Of the publications assessing the impact of guideline adherence and pregnancy outcomes,
the majority have focused on the association between weight gain and infant birth weight.
Vesco et al. and Bodnar et al. performed retrospective analyses of weight gain in obese
women. Both reported that weight gain above the guidelines was associated with an
increased risk of delivering an LGA infant, whereas less than recommended weight gain was
associated with an increased risk of delivering an SGA infant, consistent with our results.
(7,8) Most recently, two studies based on birth certificate data report similar associations
between excessive weight gain and LGA neonates and suboptimal weight gain and SGA
neonates across BMI categories. (9,10)
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Collectively, the available literature including the present study, suggests that the public
health implications of excessive weight gain during pregnancy are potentially profound. In
our study we found that the absolute risk increase of a hypertensive disorder associated with
excess weight gain was 10.9%, the absolute risk increase of cesarean delivery 8.7%, and the
absolute risk increase of delivering an LGA infant was 6.4%. If these associations were
entirely causal, and our findings were generalizable to all pregnant women in the U.S., if the
73% of women who gained above the guidelines had actually gained within the guidelines,
there would be up to 342,000 fewer cases of hypertensive disorders of pregnancy, up to
273,000 fewer cesarean deliveries, and up to 201,000 fewer LGA neonates every year
among the 4.3 million pregnancies in our country.
Our study has both strengths and limitations. The data were rigorously and prospectively
collected across multiple sites in the United States, resulting in a heterogeneous sample of
patients, thereby increasing the external validity of this study. The inclusion criteria,
nulliparous women without medical problems, were such that we were able to create a
cohort of women at a theoretically low risk of these outcomes. Further, the data were
adjusted for important confounders.
Limitations of this study include the fact that prepregnancy weight was self- reported, which
could lead to overestimation or underestimation of gestational weight gain, a common
problem in gestational weight gain studies. (11) For this reason, we also analyzed the data
based on the first recorded weight at study entry. While there were fewer women in the
normal weight and underweight BMI groups and more women in the overweight and obese
groups when analyzing recorded weights, the outcomes were not significantly different,
despite a potential misclassification bias. Furthermore, the percentage of women that gained
above, within and below the guidelines remained essentially the same. While the best
method for evaluating weight gain during pregnancy would be based on recorded weight at
conception, this is not possible. By examining the data using self- reported prepregnancy
weight and recorded weight at study entry, both of which have limitations, we were able to
show that the associations were similar. Also, while our study was large, some of the
subgroups were relatively small, and therefore, some important differences may not have
been detected due to a lack of power in individual categories. Lastly, we have examined
associations and are not able to confirm the causal implications of these data.
In summary, our study demonstrates a clear association between gestational weight gain and
pregnancy outcome. Most of the women in our study gained more weight during pregnancy
than is recommended by the current IOM guidelines and this excessive weight gain had
clear clinical downsides. Interventional trials of targeted weight gain during pregnancy are
urgently needed.
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Age (years) 22.1 ± 4.3 23.7 ± 5.3 23.9 ± 5.4 23.4 ± 5.0 <0.001
Race * <0.001
  African American 100 (25.7) 802 (17.7) 487 (25.1) 598 (41.4)
  Hispanic 108 (27.8) 1,402 (31.0) 642 (33.1) 315 (21.8)
  Caucasian 169 (43.4) 2,217 (49.0) 780 (40.3) 521 (36.1)
  Asian 8 (2.1) 71 (1.6) 16 (0.8) 4 (0.3)
  Other 4 (1.0) 30 (0.7) 12 (0.6) 7 (0.5)
Prepregnancy BMI† 17.6 ± 0.8 21.9 ± 1.7 27.1 ± 1.4 35.6 ± 5.2 <0.001
Gestational age at study entry 13.5 ± 2.1 13.5 ± 2.1 13.4 ± 2.1 13.3 ± 2.1 0.05
BMI at study entry 18.7 ± 1.3 22.7 ± 2.1 28.0 ± 2.1 36.3 ± 5.3 <0.001
Smoker 82 (21.1) 576 (12.7) 293 (15.1) 312 (21.6) <0.001
Education level (years) 12.6 ± 2.5 13.0 ± 2.8 12.7 ± 2.8 12.7 ± 2.3 <0.001
BMI, body mass index.
Data are mean ± standard deviation or number (%).
*
Race or ethnic group is self-reported.
†
Self-reported prepregnancy weight used to calculate prepregnancy body mass index.
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Weight gain above the IOM guidelines 170 (43.7) 3,190 (70.5) 1,635 (84.4) 1,063 (73.6)
Weight gain within the IOM guidelines 143 (36.8) 913 (20.2) 193 (10.0) 199 (13.8)
Weight gain below the IOM guidelines 76 (19.5) 419 (9.3) 109 (5.6) 183 (12.7)
IOM, Institute of Medicine.
Data are n (%).
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Gestational hypertension 125 (15.9) 258 (17.8) 1,436 (23.7) < 0.001
Preeclampsia 37 (4.7) 45 (3.1) 483 (8.0) < 0.001
Cesarean delivery 138 (17.5) 276 (19.1) 1,647 (27.2) < 0.001
Indicated preterm birth 25 (3.2) 35 (2.4) 173 (2.9) 0.99
Spontaneous preterm birth 66 (8.4) 75 (5.2) 283 (4.7) < 0.001
Small for gestational age† 158 (20.4) 221 (15.3) 647 (10.7) < 0.001
Large for gestational age‡ 28 (3.6) 99 (6.9) 732 (12.1) < 0.001
IOM, Institute of Medicine.
Data are n (%).
*
P values are from the Cochran-Armitage test for trend.
†
Small for gestational age defined as birth weight below the 10th percentile.
‡
Large for gestational age defined as birth weight at or above the 90th percentile.
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Gestational hypertension 2.0 (1.0–3.8) 1.5 (1.2–1.8) 1.4 (0.9–2.0) 1.2 (0.9–1.7)
Preeclampsia 3.6 (0.9–13.8) 2.5 (1.6–3.9) 4.2 (1.7–10.4) 1.9 (1.0–3.3)
Cesarean delivery 1.3 (0.7–2.5) 1.6 (1.3–2.0) 1.8 (1.2–2.6) 1.1 (0.8–1.5)
Indicated preterm birth 0.8 (0.2–4.1) 1.2 (0.7–2.1) 1.2 (0.5–3.1) 0.9 (0.4–1.8)
Spontaneous preterm birth 0.8 (0.3–1.9) 0.9 (0.6–1.3) 0.7 (0.4–1.2) 1.3 (0.6–2.6)
Small for gestational age† 0.5 (0.3–1.1) 0.6 (0.5–0.7) 0.4 (0.3–0.6) 1.0 (0.7–1.4)
Large for gestational age‡ 2.5 (1.0–6.1) 1.7 (1.3–2.3) 2.5 (1.3–4.5) 1.9 (1.0–3.7)
OR, odds ratio; CI, confidence interval.
*
Adjusted for maternal age, race, treatment group and smoking. Referent group is women gaining within the guidelines.
†
Small for gestational age defined as birth weight below the 10th percentile.
‡
Large for gestational age defined as birth weight at or above the 90th percentile.
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Gestational hypertension 0.6 (0.2–1.5) 0.7 (0.5–1.1) 0.7 (0.4–1.4) 0.7 (0.5–1.2)
Preeclampsia 2.5 (0.5–11.5) 1.3 (0.7–2.5) 1.0 (0.2–4.4) 1.1 (0.5–2.3)
Cesarean delivery 0.4 (0.2–1.1) 0.9 (0.7–1.3) 0.7 (0.4–1.4) 0.9 (0.6–1.3)
Indicated preterm birth 1.2 (0.2–8.0) 1.2 (0.5–2.7) 1.4 (0.4–5.4) 0.9 (0.4–2.4)
Spontaneous preterm birth 1.2 (0.5–3.1) 2.0 (1.3–3.2) 1.0 (0.4–2.5) 1.8 (0.7–4.2)
Small for gestational age† 1.6 (0.8–3.4) 1.3 (1.0–1.8) 0.7 (0.4–1.4) 1.7 (1.1–2.8)
Large for gestational age‡ 0.5 (0.1–2.6) 0.5 (0.3–0.8) 0.4 (0.1–1.6) 0.8 (0.3–2.2)
OR, odds ratio; CI, confidence interval.
*
Adjusted for maternal age, race, treatment group and smoking. Referent group: women gaining within the guidelines.
†
Small for gestational age defined as birth weight below the 10th percentile.
‡
Large for gestational age defined as birth weight at or above the 90th percentile.
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